ATE548381T1 - Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus - Google Patents
Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen darausInfo
- Publication number
- ATE548381T1 ATE548381T1 AT09765524T AT09765524T ATE548381T1 AT E548381 T1 ATE548381 T1 AT E548381T1 AT 09765524 T AT09765524 T AT 09765524T AT 09765524 T AT09765524 T AT 09765524T AT E548381 T1 ATE548381 T1 AT E548381T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptides
- epo
- pharmaceutical compositions
- protease resistance
- modified
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 5
- 102000003951 Erythropoietin Human genes 0.000 title abstract 3
- 108090000394 Erythropoietin Proteins 0.000 title abstract 3
- 229940105423 erythropoietin Drugs 0.000 title abstract 2
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000037081 physical activity Effects 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13037608P | 2008-05-29 | 2008-05-29 | |
| PCT/EP2009/003862 WO2009152944A1 (en) | 2008-05-29 | 2009-05-29 | Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE548381T1 true ATE548381T1 (de) | 2012-03-15 |
Family
ID=40943614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09765524T ATE548381T1 (de) | 2008-05-29 | 2009-05-29 | Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120264686A9 (de) |
| EP (1) | EP2297197B1 (de) |
| JP (1) | JP2011520472A (de) |
| KR (1) | KR101275950B1 (de) |
| CN (1) | CN102186879A (de) |
| AT (1) | ATE548381T1 (de) |
| WO (1) | WO2009152944A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| US9321999B2 (en) * | 2009-11-19 | 2016-04-26 | Solis Biodyne Oü | Compositions for increasing polypeptide stability and activity, and related methods |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (de) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Manipulierte nukleinsäuren und anwendungsverfahren dafür |
| AU2012251919B2 (en) | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052521A1 (de) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynukleotide zur codierung von low-density-lipoprotein-rezeptor |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3194429A4 (de) * | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Neuartige feline erythropoietinrezeptor-agonisten |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| KR101947342B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | Gm-csf 반감기를 증가시키는 방법 |
| CN107898812A (zh) * | 2017-12-06 | 2018-04-13 | 广州瑞铂茵健康管理咨询有限公司 | 一种基于脐带干细胞及活性成分的软骨损伤混合修复液 |
| CN110093336B (zh) * | 2018-01-29 | 2023-03-24 | 上海雅心生物技术有限公司 | 一种稳定的胰蛋白酶及其制备方法 |
| WO2019173283A1 (en) | 2018-03-05 | 2019-09-12 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| CN110241130B (zh) * | 2018-03-09 | 2023-04-14 | 中国科学院分子植物科学卓越创新中心 | 控制植物粒数和粒重的gsn1基因、编码蛋白及其应用 |
| AR113091A1 (es) | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
| US20230151071A1 (en) * | 2020-04-09 | 2023-05-18 | United States Government As Represented By The Department Of Veterans Affairs | Compositions comprising recombinant epo and methods of use thereof |
| US20230405086A1 (en) * | 2020-05-01 | 2023-12-21 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for preventing, detecting, and treating inflammatory bowel disease |
| EP3916008A1 (de) * | 2020-05-26 | 2021-12-01 | Sylus Co., Ltd. | Neues peptid und verwendung davon zur behandlung von erkrankungen des gehirns und nervensystems |
| IL301441A (en) * | 2020-09-30 | 2023-05-01 | Realta Life Sciences Inc | Peptides and methods of use |
| EP4247839A2 (de) * | 2020-11-18 | 2023-09-27 | Chulabhorn Foundation | Erythropoietinvarianten und verwendungen davon |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
| CN117069825A (zh) * | 2022-05-17 | 2023-11-17 | 广州汉腾生物科技有限公司 | 重组促红细胞生成素及其应用 |
| CN116732012A (zh) * | 2023-03-13 | 2023-09-12 | 山东舜丰生物科技有限公司 | 碱基编辑器及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03151399A (ja) * | 1989-11-07 | 1991-06-27 | Snow Brand Milk Prod Co Ltd | 変異ヒトエリスロポエチン |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US20040063917A1 (en) * | 2001-02-06 | 2004-04-01 | Carr Francis J. | Modified erythropoietin (epo) with reduced immunogenicity |
| WO2003055526A2 (en) * | 2001-12-21 | 2003-07-10 | Maxygen Aps | Erythropoietin conjugates |
| US20050202438A1 (en) | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| AU2003267700A1 (en) | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US20060020396A1 (en) | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| CN100405906C (zh) * | 2002-10-09 | 2008-07-30 | 尼奥斯技术有限公司 | 促红细胞生成素:促红细胞生成素的重构和糖缀合 |
| US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
| CA2563874A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| US20060073563A1 (en) * | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
| GB0500099D0 (en) * | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
| WO2008065372A2 (en) * | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
-
2009
- 2009-05-29 EP EP09765524A patent/EP2297197B1/de not_active Not-in-force
- 2009-05-29 WO PCT/EP2009/003862 patent/WO2009152944A1/en not_active Ceased
- 2009-05-29 US US12/736,959 patent/US20120264686A9/en not_active Abandoned
- 2009-05-29 CN CN2009801298231A patent/CN102186879A/zh active Pending
- 2009-05-29 JP JP2011510898A patent/JP2011520472A/ja active Pending
- 2009-05-29 AT AT09765524T patent/ATE548381T1/de active
- 2009-05-29 KR KR1020107029475A patent/KR101275950B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120264686A9 (en) | 2012-10-18 |
| CN102186879A (zh) | 2011-09-14 |
| KR20110022638A (ko) | 2011-03-07 |
| KR101275950B1 (ko) | 2013-06-25 |
| WO2009152944A1 (en) | 2009-12-23 |
| US20120094906A1 (en) | 2012-04-19 |
| EP2297197A1 (de) | 2011-03-23 |
| JP2011520472A (ja) | 2011-07-21 |
| EP2297197B1 (de) | 2012-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE548381T1 (de) | Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus | |
| WO2008065372A3 (en) | Modified erythropoietin polypeptides and uses thereof for treatment | |
| JOP20190083B1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| CY1121327T1 (el) | Τροποποιημενα αντισωματα anti-il-23p19 | |
| WO2007110231A3 (en) | MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
| MX2011013903A (es) | Polipeptidos quimericos y usos de los mismos. | |
| CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
| EP2568996A4 (de) | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen | |
| NO20082531L (no) | Neuropilinantagonister | |
| EP2563912A4 (de) | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von asparaginyl-trna-synthetasen | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| BRPI0609797B8 (pt) | nanocorpos melhorados para o tratamento de desordens mediadas por agregação | |
| BR112013010857A2 (pt) | imonoglubulinas de duplo domínio variável e usos das mesmas | |
| CL2007003629A1 (es) | Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos. | |
| WO2007133835A8 (en) | Ras mutation and compositions and methods related thereto | |
| BR112014032316A2 (pt) | proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta | |
| MY177970A (en) | Bcma (cd269/tnfrsf17) -binding proteins | |
| EA201101523A1 (ru) | Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| EP2563911A4 (de) | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von alanyl-trna-synthetasen | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| ATE489371T1 (de) | Benzamidglucokinaseaktivatoren | |
| CL2008000875A1 (es) | Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras. |